Mandate

Vinge has advised Vicore Pharma Holding AB (publ) in connection with a directed share issue

Vinge has advised Vicore Pharma Holding AB (publ) in connection with a directed share issue, whereby Vicore Pharma receives gross proceeds of SEK 200 million.

The share issue was directed to a number of Swedish and international institutional investors on the basis of an accelerated bookbuilding process. Vicore Pharma intends to use the issue proceeds to finance preparations for Phase 2b trial in idiopathic pulmonary fibrosis (IPF) including scale-up and manufacturing whilst continuing and completing the IPF AIR trial.

Vinge’s team has consisted of Rikard Lindahl, Joel Magnusson and Annie Fällström.

 

Related

Vinge has advised Fortinova Fastigheter in connection with its uplisting to Nasdaq Stockholm

Vinge has advised Fortinova Fastigheter AB (publ) in connection with its list change from Nasdaq First North Premier Growth Market to Nasdaq Stockholm. The prospectus was published on 12 November 2025 and the trading on Nasdaq Stockholm commenced on 19 November 2025, five years to the day since the first listing.
November 19, 2025

Vinge has advised Lagercrantz Group on the acquisition of Sit Right and Enskede Hydraul

Lagercrantz Group AB (publ) has acquired 70 percent of the shares in the two Swedish companies Sit Right AB and Enskede Hydraul AB, which are leading operators in products and aftermarket parts for forestry and construction machinery in Europe.
November 07, 2025

Vinge advises the founders of NOOS Digital in connection with the merger with Rocket Revenue and 56K Digital

Following the recent merger between Rocket Revenue and 56K Digital, the group now takes its next step by joining forces with NOOS Digital. The three companies will integrate into one of the Nordic region’s most comprehensive partners for digital transformation and business acceleration.
November 04, 2025